Home/Filings/4/0001231589-26-000002
4//SEC Filing

MAHON PAUL A 4

Accession 0001231589-26-000002

CIK 0001082554other

Filed

Jan 14, 7:00 PM ET

Accepted

Jan 15, 4:32 PM ET

Size

18.5 KB

Accession

0001231589-26-000002

Insider Transaction Report

Form 4
Period: 2026-01-15
MAHON PAUL A
EVP & GENERAL COUNSEL
Transactions
  • Exercise/Conversion

    Common Stock

    [F1]
    2026-01-15$146.03/sh+8,300$1,212,04945,081 total
  • Sale

    Common Stock

    [F1][F2]
    2026-01-15$468.32/sh1,439$673,91843,642 total
  • Sale

    Common Stock

    [F1][F3]
    2026-01-15$470.37/sh1,307$614,76942,335 total
  • Sale

    Common Stock

    [F1][F4]
    2026-01-15$472.28/sh407$192,21941,928 total
  • Sale

    Common Stock

    [F1][F5]
    2026-01-15$469.34/sh3,531$1,657,23738,397 total
  • Sale

    Common Stock

    [F1][F6]
    2026-01-15$471.44/sh1,576$742,99036,821 total
  • Sale

    Common Stock

    [F1]
    2026-01-15$474.74/sh40$18,99036,781 total
  • Exercise/Conversion

    Stock Option

    [F1]
    2026-01-158,30058,400 total
    Exercise: $146.03From: 2020-03-15Exp: 2027-03-15Common Stock (8,300 underlying)
Footnotes (6)
  • [F1]This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025.
  • [F2]This transaction was executed in multiple trades at prices ranging from $467.815 to $468.80. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  • [F3]This transaction was executed in multiple trades at prices ranging from $469.92 to $470.64. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  • [F4]This transaction was executed in multiple trades at prices ranging from $472.13 to $472.73. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  • [F5]This transaction was executed in multiple trades at prices ranging from $468.84 to $469.82. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  • [F6]This transaction was executed in multiple trades at prices ranging from $471.00 to $471.99. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Signature
/s/ John S. Hess, Jr. under Power of Attorney|2026-01-15

Issuer

UNITED THERAPEUTICS Corp

CIK 0001082554

Entity typeother

Related Parties

1
  • filerCIK 0001231589

Filing Metadata

Form type
4
Filed
Jan 14, 7:00 PM ET
Accepted
Jan 15, 4:32 PM ET
Size
18.5 KB